Table 2.
Vaccine formulation | Ab response (D28) | Th1 response (D14/D28) | Th17 response (D14/D28) | Early inflam. BTM | Early IFN type I BTM | Early myeloid cell/DC BTM | Late cell cycle BTM | Late T/NK-cell BTM | Late Ig BTM |
---|---|---|---|---|---|---|---|---|---|
Lipo_AMP | ++ | + | – | +++ | + | +++ | ++ | ++ | ++ |
Lipo_TLR | + | + | – | + | + | + | ++ | ++ | ++ |
PLGA_TLR | – | – | + | – | – | – | – | – | – |
SWE_TLR | + | ++ | – | ++ | ++ | ++ | – | – | +++ |
Lipo_DDA:TDB | ++ | +++ | – | + | – | ++ | – | – | ++ |
Hyogen | ++ | + | – | + | – | ++ | – | – | ++ |
Six animals per group were prime-boost vaccinated on D0 and D14. Ab, antibody; Th, T helper; BTM, blood transcriptional modules; early, upregulation from D0 to D1; late, upregulation from D1 to D7; –, none to weak; +, moderate; ++, strong; +++, very strong.